Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate

A Crilly; I B McInness; A G McDonald; J Watson; H A Capell; R Madhok

Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate

A Crilly
, I B McInness
, A G McDonald
, J Watson
, H A Capell
, R Madhok

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: To investigate the effect of oral methotrexate (MTX) on circulating levels of interleukin 6 (IL-6) and soluble IL-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).

METHODS: We measured serum concentrations of IL-6 (n = 20) and sIL-2R (n = 16) before MTX therapy and again after 12 weeks.

RESULTS: MTX significantly reduced IL-6 and sIL-2R after 12 weeks of therapy, and although the levels remained low at 24 weeks of therapy, the reduction was not significant. Reduction in cytokine levels was paralleled by an improvement in clinical indices. Placebo treatment did not significantly alter IL-6 or sIL-2R.

CONCLUSION: MTX appears capable of cytokine modulation, although the mechanism is not clear.

Original language	English
Pages (from-to)	224-6
Number of pages	3
Journal	The Journal of Rheumatology
Volume	22
Issue number	2
Publication status	Published - Feb 1995

Keywords

Administration, Oral
Arthritis, Rheumatoid
Dose-Response Relationship, Drug
Humans
Interleukin-6
Methotrexate
Middle Aged
Receptors, Interleukin-2
Solubility

Cite this

@article{00eef440609f45ffabab15d4e116d006,

title = "Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate",

abstract = "OBJECTIVE: To investigate the effect of oral methotrexate (MTX) on circulating levels of interleukin 6 (IL-6) and soluble IL-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).METHODS: We measured serum concentrations of IL-6 (n = 20) and sIL-2R (n = 16) before MTX therapy and again after 12 weeks.RESULTS: MTX significantly reduced IL-6 and sIL-2R after 12 weeks of therapy, and although the levels remained low at 24 weeks of therapy, the reduction was not significant. Reduction in cytokine levels was paralleled by an improvement in clinical indices. Placebo treatment did not significantly alter IL-6 or sIL-2R.CONCLUSION: MTX appears capable of cytokine modulation, although the mechanism is not clear.",

keywords = "Administration, Oral, Arthritis, Rheumatoid, Dose-Response Relationship, Drug, Humans, Interleukin-6, Methotrexate, Middle Aged, Receptors, Interleukin-2, Solubility",

author = "A Crilly and McInness, \{I B\} and McDonald, \{A G\} and J Watson and Capell, \{H A\} and R Madhok",

year = "1995",

month = feb,

language = "English",

volume = "22",

pages = "224--6",

journal = "The Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "2",

}

TY - JOUR

T1 - Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate

AU - Crilly, A

AU - McInness, I B

AU - McDonald, A G

AU - Watson, J

AU - Capell, H A

AU - Madhok, R

PY - 1995/2

Y1 - 1995/2

N2 - OBJECTIVE: To investigate the effect of oral methotrexate (MTX) on circulating levels of interleukin 6 (IL-6) and soluble IL-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).METHODS: We measured serum concentrations of IL-6 (n = 20) and sIL-2R (n = 16) before MTX therapy and again after 12 weeks.RESULTS: MTX significantly reduced IL-6 and sIL-2R after 12 weeks of therapy, and although the levels remained low at 24 weeks of therapy, the reduction was not significant. Reduction in cytokine levels was paralleled by an improvement in clinical indices. Placebo treatment did not significantly alter IL-6 or sIL-2R.CONCLUSION: MTX appears capable of cytokine modulation, although the mechanism is not clear.

AB - OBJECTIVE: To investigate the effect of oral methotrexate (MTX) on circulating levels of interleukin 6 (IL-6) and soluble IL-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).METHODS: We measured serum concentrations of IL-6 (n = 20) and sIL-2R (n = 16) before MTX therapy and again after 12 weeks.RESULTS: MTX significantly reduced IL-6 and sIL-2R after 12 weeks of therapy, and although the levels remained low at 24 weeks of therapy, the reduction was not significant. Reduction in cytokine levels was paralleled by an improvement in clinical indices. Placebo treatment did not significantly alter IL-6 or sIL-2R.CONCLUSION: MTX appears capable of cytokine modulation, although the mechanism is not clear.

KW - Administration, Oral

KW - Arthritis, Rheumatoid

KW - Dose-Response Relationship, Drug

KW - Humans

KW - Interleukin-6

KW - Methotrexate

KW - Middle Aged

KW - Receptors, Interleukin-2

KW - Solubility

M3 - Article

C2 - 7738942

SN - 0315-162X

VL - 22

SP - 224

EP - 226

JO - The Journal of Rheumatology

JF - The Journal of Rheumatology

IS - 2

ER -

Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate

Abstract

Keywords

Fingerprint

Cite this